Antonio Wolff, MD
Medical Oncology · Lutherville, MDNPI 1861420291
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,530 of the $14,109 with a category attached, or 95.9%. F. Hoffmann-la Roche AG accounts for 72.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $6,942 and has fallen 98.6% since, to $99 in 2024.
Across 11 payments — averaging $1282.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- F. Hoffmann-la Roche AG$10K
- Roche Products Limited$3K
- Astrazeneca UK Limited$243
- Gilead$137
- AstraZeneca$100
- Novartis$99
Across 94 payments — averaging $53,189 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Macrogenics, Inc.$4.2M
- Genentech, Inc.$636K
- Gilead$101K
- Roche Products Limited$24K
- Hoffmann-la Roche Limited$19K
- Pfizer$10K
- plus $13K from 3 others
What the payments were for
- Consulting fees$13,53096%
- Food & beverage$5674%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| F. Hoffmann-la Roche AG | 3 | $10,230 |
| Roche Products Limited | 1 | $3,300 |
| Astrazeneca UK Limited | 2 | $243 |
| Gilead | 2 | $137 |
| AstraZeneca | 2 | $100 |
| Novartis | 1 | $99 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,109 in reported general payments places this provider in the 65th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 21 | $322,208 |
| Letrozole | 97 | $3,536 |
| Exemestane | 20 | $2,205 |
| Tamoxifen Citrate | 47 | $1,536 |
| Anastrozole | 11 | $140 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Lutherville
- William SharfmanLutherville$112K
- Deborah ArmstrongLutherville$34K
- David EttingerLutherville$13K
- Mario EisenbergerBaltimore$2.9M
- Adrian SenderowiczBethesda$1.6M
- Mohit NarangOwing Mills$1.3M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.